Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

A Battle Between Two Vaccine Makers

Stock MarketsOct 10, 2021 01:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. A Battle Between Two Vaccine Makers

Pfizer (NYSE:PFE) and Moderna (NASDAQ:NASDAQ:MRNA) are two of the bioscience companies that are facilitating global vaccines. I'm bullish on Pfizer but bearish on Moderna.

See Top Smart Score Stocks >>

Using TipRanks' Stock Comparison tool, we can compare the two vaccine stocks.


Pfizer was already producing stellar financial results prior to COVID-19; in 2019, operating income grew by 13.29%, with the company's wide range of approved drugs contributing to growth.

In 2020, Pfizer spent a lot of capital on Research & Development for the COVID-19 vaccine, which meant that operating income didn't improve all that much in 2020 (+20.89%), even after the vaccine rollout started.

However, in 2021, Pfizer's income statement took off, as operating income has risen by 159.42% year-over-year.

Research & Development costs are predicted to flatline for now, while the company's topline revenue is anticipated to grow even further, as booster shots are likely to be consolidated.

Pfizer is in a good spot from a value perspective: the stock's PEG ratio (0.26) is trading well below the overvalued benchmark (1.00), and its PE ratio is trading below its 5-year average by 1.45%.

Furthermore, Pfizer offers an attractive dividend, with a yield of 3.64% and 11 consecutive years of growth. The cash payout ratio is at a 32.42% discount to its 5-year average, which means that there's plenty of room left for dividend increases in the future.

Wall Street thinks Pfizer stock is a Hold, with an average Pfizer price target of $45.55, implying upside of 7.30%. There have been 2 Buy ratings on the stock, 9 Hold ratings, and no Sell ratings.


Moderna wasn't well-known to most before its discovery of the initial COVID-19 vaccine. In the years prior to the vaccine rollout, Moderna was burning through capital and sustaining heavy operating losses; in 2019 the company had operating losses of 940%.  

In 2020, the operating losses narrowed to -36%, but over the past year an operating profit of 54.39% was achieved as it rolled out its vaccines.

Moderna's financial statements could continue to benefit from booster shots, but its reliance on the COVID vaccine alone ensures that the stock is in overvalued territory.

Moderna isn't profitable unless it converts its financial statements to U.S. accounting standards, where it has a PE ratio of 33.37, which is twice as high as Pfizer's. Furthermore, the company's trading at a price to sales ratio that is 129.51% higher than the sector average; this is underappreciated considering the large spike in vaccine sales.

Lastly, unlike Pfizer, Moderna doesn't pay a dividend. Investors are likely to seek dividends going into Q-4 and Q-1 in 2022, as the market could face a drawdown. Moderna's not capable of paying a dividend because it won't be able to sustain its net income without regular mass vaccine rollouts.

Wall Street thinks Moderna is a Hold, with an average Moderna price target of $363.13, implying upside of 19.09%. There have been 3 Buy ratings on the stock, 7 Hold ratings, and 2 Sell ratings.

Final Word

Pfizer could still be worth buying, because of the company's solid history and its dividend capacity. Moderna was a sporadic beneficiary of the vaccine rollout, but I anticipate the overvalued stock to draw down, even given the possibility of regular booster shots.

Disclosure: At the time of publication, Steve Gray Booyens did not have a position in any of the securities mentioned in this article.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

A Battle Between Two Vaccine Makers

Related Articles

Danone doubles supply of some baby formula to U.S.
Danone doubles supply of some baby formula to U.S. By Reuters - May 25, 2022

By Richa Naidu LONDON (Reuters) - Danone SA (OTC:DANOY) on Wednesday said it has been doubling shipments to the United States of Neocate formula for infants allergic to cow's...

Britain's M&S warns on outlook after profit jump
Britain's M&S warns on outlook after profit jump By Reuters - May 25, 2022

LONDON (Reuters) -British retailer Marks & Spencer (OTC:MAKSY) joined rivals in warning on the outlook for the current year amid a worsening cost-of-living crunch, taking the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
John Laurens
John Laurens Oct 10, 2021 6:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All about the money and the payola to the fascist dems in the US.. Pretty soon they're gonna push vaccines on babies.. lol
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email